ArticleArchives of virology2025
MF59-like adjuvant containing yeast-derived squalene enhances the humoral immune response to cell-derived influenza vaccine.
Article in Archives of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The aims of this study were to assess the adjuvant properties of an MF59-like adjuvant containing yeast-derived squalene (MF59-like YD) in a cell-based quadrivalent influenza vaccine (QIV) and to investigate the potential mechanisms of action. MF59-like adjuvants containing either yeast-derived or shark-derived squalene were incorporated into QIV formulations. Antigen-specific immune responses in mouse serum were evaluated via enzyme-linked immunosorbent assays (ELISAs), hemagglutination inhibition (HI) assays, and microneutralization (MN) assays. The effects and mechanisms of action of the adjuvants were further analyzed by analyzing mouse spleen germinal center (GC) cell activation via flow cytometry. MF59-like YD significantly increased the humoral immune responses induced by QIVs in mice, in particular, the titers of HI and MN antibodies against homologous and heterologous virus subtypes. Mechanistically, MF59-like YD increased the immune response to influenza vaccines by activating T follicular helper (Tfh) and B cells in the GC. Given the greater availability of yeast-derived squalene and the finding that its adjuvant efficacy was comparable to that of shark-derived squalene, we propose that the MF59-like YD adjuvant is a promising alternative adjuvant for future influenza vaccines.
Indexed as
Identifiers
40399654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.